1. Aarhus, Denmark

2.  Meta-IQ develop medicine for the treatment of brain diseases like Alzheimer, Depression and Multiple Sclerosis by influencing the metabolism  Meta-IQ was founded February 2008 by Jette and John Nieland  Meta-IQ is a story of coincidence, innovative thinking, not giving up and your chance to be part of history and on the way gain something from it Jette and John Nieland 20102

3.  Jette G. K. Nieland, CEO, MSc in clinical and business psych. Responsible for financial and business development  John D. Nieland, COO, Assoc. prof. biotech., Ph.D. in medicine Responsible for research and organization of clinical trials Jette and John Nieland 20103

4.  Mogens Kloth-Malmqvist Business manager MK Invest & Consulting GmbH  Peter Heinrich Key advisorMagForce nanotechnologies AG  Martin KlothBusiness controllerMK Invest & Consulting GmbH  Jakob Krag NielsenContractsPlessner  Ulla KlingePatent Inspicos A/S  Jens FahlbergCertified tax advisor Rådgivning & Revision A/S  Ove WiborgResearchAarhus University Hospital Jette and John Nieland 20094

5.  Your body is controlled by your brain which controls it by sending signals (energy package) through your body  There are 2 energy sources for cells, glucose and fatty acids  Different kind of stress makes the metabolism shift from a glucose to fatty acid metabolism  A cascade of processes is starting in the brain, which can lead to different brain diseases.  The balace between metabolism, immune system and CNS is challenged Jette and John Nieland 20105

6.  The only way to block all these processes effectively is by reversing the energy generation.  We treat the disease by blocking fatty acid metabolism  We reset the body functions and restore the balance in the system  We force the normal body functions to take care of the disease itself  We treat patients for weeks not for years Jette and John Nieland 20106

7. Palmitate coupled to Myelin is the isolation around nerve cells Jette and John Nieland 20107 Blocking fatty acid metabolism reverts the disease inducing cascade

8. Jette and John Nieland 20098

9. Jette and John Nieland 20109 Rats are stressed for several week after which 50% get depressed. Then the depressed animal are treated either with M-IQ 002 or placebo. As a control normal animals are treated with either M-IQ 002 or placebo. Within 1 week up to 70 % and within 4 weeks 95% of the animals respond. Normal medicine on the market gives maximally 50% response rate after completion of treatment. 0 20 40 60 80 100 before treatmentweek 1week 4 % Normal Animals NormalStressed M-IQ 002Stressed Vehicle

10. Jette and John Nieland 201010 The responding animals show maximal response within 1 week of treatment, in contrast medicine on the market takes about 3-4 week before an effect starts being visible. Escitralopram data are from historic experiments as comparison

11. Jette and John Nieland 200911

12.  Depression (MIQ-002) Of the animals; 70% within 1 week and 95% after 4 weeks are cured Medicine on the market gives maximally 50% response rate in a 6 weeks treatment with the first effects visible after 3 - 4 weeks  Alzheimer (MIQ-001) A one day treatment with MIQ 001 restores; 40% long term memory 60% short term memory  Multiple Sclerosis (MIQ-003) 50% of the diseased animals are cured within 2 weeks of treatment Jette and John Nieland 201012

13.  Depression (MIQ-002) Depression is the most prevalent psychological disease over 10 % of the population suffer from it The annual market is 12 billion USD  Alzheimer (MIQ-001) 1% of people will get Alzheimer, and over 65 years it goes up to 5% The annual market is 5 billion USD  Multiple Sclerosis (MIQ-003) Worldwide about 2,5 million people suffer from multiple sclerosis for which there is no treatment available The annual market is 5 billion USD Jette and John Nieland 201013

14.  The global rights The global rights have been in-licensed to these compounds for all disease indications  Manufacturing process established Active Pharmaceutical ingredient (API) is available at GMP-grade (Good Manufacturing Praxis)  Pre-clinical development,Pharm/Toxic studies completed Toxicity pharmacology package is complete to start human clinical phase 2 trials  Proof of concept reached Proof of concepts for Alzheimer and the treatment of Depression has been reached  We have filed patents Patents cover the product for the treatment of brain and other diseases and will give protection until 2029  Due diligence of Meta-IQ June 2010 MedTech Innovation Center, Aarhus arranged due diligence of Meta-IQ with a very positive outcome Jette and John Nieland 201014

15.  Meta-IQ is looking for a 7 million € investment to start the clinical phase 2 trial in depression and a small phase I trial in Alzheimer  To go into phase 2 trials for Alzheimer or Multiple Sclerosis we need an additional 3 million € for each indication Jette and John Nieland 201015

16.  In the first year: Formulate medicine, get ethical and medical comity approval for clinical trial  In the second year: Run phase 2 clinical trial in Depression and after 6 months start a phase I clinical trial in Alzheimer  In the third year: Analyze the results of the depression study and out-license or sell project to big pharma company. Finish clinical trial in Alzheimer and start evaluating results Jette and John Nieland 201016

17. 1. Develop projects through phase 1 and 2 clinical trials 2. Out-license or sell projects to Big Pharma 3. Develop own projects 4. In-license projects Jette and John Nieland 201017

18.  To investors we offer the opportunity of being part of making new history in treating brain diseases  Promising financial perspectives in relation to the risks of the project Because of the know how, CMC, preclinical and clinical data in Meta-IQ  The medicine can reach a leading position in major indications  For investors, a possibility of an exit after 3 years Jette and John Nieland 201018

19. You can invest in this dynamic and innovative company and make profit in 3 years You or your family will be able to gain from its medicine in 8 years Thank you for your attention